Skip to main content
Evidence Snapshot

Leishmania mexicana

CHEMBL612880 ORGANISM Leishmania mexicana
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:25:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612880
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Leishmania mexicana as ChEMBL target CHEMBL612880. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Leishmania mexicana
ORGANISM · Leishmania mexicana
As of 2026-09-13
ChEMBL target ID
CHEMBL612880
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Leishmania mexicana matters

As of 2026-09-13

Leishmania mexicana is reviewed as Leishmania mexicana; the current evidence base includes 10 approved drugs, 837 compounds, and 141 assays, with lead potency reaching pChEMBL 8.0.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 10 approved drugs, 837 compounds, and 141 assays for this target. The dominant activity type is IC50. CHEMBL561057 is the current potency anchor at pChEMBL 8.0.

Use CHEMBL561057 as the tractability anchor when discussing potency (pChEMBL 8.0).

Activity source · ChEMBL 36 via Core Engine
10 approved pChEMBL 8.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Leishmania mexicana matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

837
Total Compounds
141
Total Assays
10
Approved Drugs
IC50: 344.0, EC50: 342.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL561057
 8.0 IC50 Clinical
No preferred name
CHEMBL5549773
 8.0 EC50 —
No preferred name
CHEMBL5542939
 7.8 EC50 —
No preferred name
CHEMBL5562085
 7.8 EC50 —
No preferred name
CHEMBL5559625
 7.7 EC50 —

Approved Drugs

Structure Compound First Approval
PENTAMIDINE
CHEMBL55
 1984
AMPHOTERICIN B
CHEMBL267345
 1964
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:25:03Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL612880